新一代可吸收合成补片修补食管裂孔疝的四年单中心经验
该单中心研究基于前瞻性数据库,纳入2017年12月至2022年7月共97例接受生物合成可吸收补片(BSM)加强修补的食管裂孔疝患者,评估围术期并发症、功能结果与复发率。结果显示无围术期死亡,总体并发症(Clavien-Dindo≥2)为15%、严重并发症(≥3b)为3%,中位随访12个月时74%无症状、10%临床失败、2%需再次手术。作者认为BSM加强修补可行且安全,早中期失败率可接受。
要点
- BSM加强修补食管裂孔疝无围术期死亡,总体并发症15%、严重并发症3%。
- 中位随访12个月,74%患者无症状,10%临床失败,2%需再次手术。
- 择期初次手术无并发症比例88%,急诊病例仅25%,提示急诊条件更差。
核心结论
- BSM加强修补食管裂孔疝可行且安全,围术期并发症低,早中期随访失败率可接受,可能成为不可吸收材料的替代选择。
研究设计与样本
- 单中心前瞻性数据库研究,纳入2017年12月至2022年7月连续97例接受BSM加强修补的食管裂孔疝患者,其中择期初次手术76例、再次手术13例、急诊8例。
主要发现
- 无围术期死亡,总体并发症(Clavien-Dindo≥2)15%、严重并发症(≥3b)3%,无并发症比例85%。
- 中位(IQR)随访12个月时,69例(74%)无症状、15例(16%)改善、9例(10%)临床失败,其中2例(2%)需再次手术。
- 择期初次手术无并发症88%、再次手术100%、急诊25%。
- 择期与急诊病例指征中食管旁疝(II-IV型)占83%,大型I型疝占4%。
关键数值与推荐
- 总体并发症定义为Clavien-Dindo≥2,严重并发症定义为Clavien-Dindo≥3b。
- 功能结局按无症状、改善、临床失败分类,临床失败中需再次手术者单独统计。
临床怎么用
- 对适合补片加强的食管裂孔疝患者,可考虑使用BSM以规避不可吸收合成材料与生物材料的缺点。
- 急诊病例无并发症比例明显低于择期病例,应审慎评估急诊条件下的补片加强策略。
局限性
- 单中心回顾性数据提取,样本量97例,随访中位仅12个月,缺乏对照组,长期复发数据不足。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Mesh augmentation is a highly controversial adjunct of hiatus hernia (HH) surgery. The current scientific evidence remains unclear and even experts disagree on indications and surgical techniques. With an aim to avoid the downsides of both non-resorbable synthetic and biological materials, biosynthetic long-term resorbable meshes (BSM) have recently been developed and are becoming increasingly popular. In this context, we aimed at assessing outcomes after HH repair with this new generation of mesh at our institution. METHODS: From a prospective database, we identified all consecutive patients that underwent HH repair with BSM augmentation. Data was extracted from electronic patient charts of our hospital information system. Endpoints of this analysis included perioperative morbidity, functional results and recurrence rates at follow-up. RESULTS: Between December 2017 and July 2022, 97 patients (elective primary cases n = 76, redo cases n = 13, emergency cases n = 8) underwent HH with BSM augmentation. Indications in elective and emergency cases were paraesophageal (Type II-IV) HH in 83%, and large Type I HH in 4%. There was no perioperative mortality, and overall (Clavien-Dindo ≥ 2) and severe (Clavien-Dindo ≥ 3b) postoperative morbidity was 15% and 3%, respectively. An outcome without postoperative complications was achieved in 85% of cases (elective primary surgery 88%, redo cases 100%, emergencies cases 25%). After a median (IQR) postoperative follow-up of 12 months, 69 patients (74%) were asymptomatic, 15 (16%) reported improvement, and 9 (10%) had clinical failure, of which 2 patients (2%) required revisional surgery. CONCLUSION: Our data suggest that HH repair with BSM augmentation is feasible and safe with low perioperative morbidity and acceptable postoperative failure rates at early to mid-term follow-up. BSM may be a useful alternative to non-resorbable materials in HH surgery.
引用
- Ukegjini K, Vetter D, Dirr V, et al. Hiatus hernia repair with a new-generation biosynthetic mesh: a 4-year single-center experience. Surg Endosc. 2023. PMID: 36976420. doi:10.1007/s00464-023-10005-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。